SEC Comment Letter for Lite Strategy, Inc. (LITS) (CIK 0001262104) (LITS) — May 10, 2017
Lite Strategy, Inc. (LITS) (CIK 0001262104)
Date: May 10, 2017 · CIK: 0001262104 · Accession: 0000000000-17-016478
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-217645
Letter
Mail Stop 4546 May 10 , 2017 Daniel P. Gold President and Chie f Executive Officer MEI Pharma, Inc. 11975 El Camino Real, Suite 101 San Diego, CA 92130
Re: MEI Pharma, Inc. Registration Statement on Form S-3 Filed May 4 , 2017 File No. 333-217645
Dear Mr. Gold :
This is to advise you that we have not reviewed and will not review your registration statement .
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at (202) 551 -5019 with any questions.
Sincerely,
/s/ Mary Beth Breslin for
Show Raw Text
Mail Stop 4546 May 10 , 2017 Daniel P. Gold President and Chie f Executive Officer MEI Pharma, Inc. 11975 El Camino Real, Suite 101 San Diego, CA 92130 Re: MEI Pharma, Inc. Registration Statement on Form S-3 Filed May 4 , 2017 File No. 333-217645 Dear Mr. Gold : This is to advise you that we have not reviewed and will not review your registration statement . Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at (202) 551 -5019 with any questions. Sincerely, /s/ Mary Beth Breslin for Suzanne Hayes Assistant Director Office of Healthcare and Insurance cc: Steven A. Navarro, Esq. Morgan, Lewis & Bockius LLP